PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM)

被引：3
|
作者：
Alsina, M.
Lonial, S.
Weber, D. M.
Coutre, S. E.
Kang, B. P.
Glynos, T.
Warsi, G.
Snodgrass, S. M.
Richardson, P. G.
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS308
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1
    San-Miguel, Jesus F.
    de Moraes Hungria, Vania Tietsche
    Yoon, Sung-Soo
    Wiktor-Jedrzejczak, Wieslaw
    Elghandour, Ashraf
    Siritanaratkul, Noppadol
    Dimopoulos, Meletios Athanasios
    Corradini, Paolo
    Nakorn, Thanyaphong Na
    Shelekhova, Tatiana
    Guenther, Andreas
    Yong, Kwee
    Schlossman, Robert
    Wroclawska-Swacha, Monika
    Weber, Hans-Jochen
    Bourquelot, Priscille
    Hou, Jian
    Einsele, Hermann
    Lee, Jae Hoon
    Moreau, Philippe
    Lonial, Sagar
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 1701 - 1702
  • [22] Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM)
    Berenson, James R.
    Hilger, James D.
    Dichmann, Robert
    Patel-Donnelly, Dipti
    Boccia, Ralph V.
    Bessudo, Alberto
    Stampleman, Laura
    Gravenor, Donald
    Eshaghian, Shahrooz
    Chamras, Hilda
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
    Pour, Ludek
    Efebera, Yvonne
    Granell, Miquel
    Hajek, Roman
    Oriol, Albert
    Delaunay, Jacques
    Le Du, Katell
    Eveillard, Jean-Richard
    Karlin, Lionel
    Maisnar, Vladimir
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Moreb, Jan
    Ribrag, Vincent
    Richardson, Paul G.
    Straub, Jan
    Byrne, Catriona
    Jacques, Christian
    Zubair, Hanan
    Ocio, Enrique
    CANCER RESEARCH, 2019, 79 (13)
  • [25] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Mu, Song
    Kuroda, Yoshiaki
    Shibayama, Hirohiko
    Hino, Masayuki
    Tajima, Takeshi
    Corrado, Claudia
    Lin, Rong
    Waldron, Edward
    Binlich, Florence
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 153 - 161
  • [26] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Song Mu
    Yoshiaki Kuroda
    Hirohiko Shibayama
    Masayuki Hino
    Takeshi Tajima
    Claudia Corrado
    Rong Lin
    Edward Waldron
    Florence Binlich
    Kenshi Suzuki
    European Journal of Clinical Pharmacology, 2016, 72 : 153 - 161
  • [27] Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Banwait, Ranjit
    Poon, Tiffany
    Campigotto, Federico
    Boswell, Erica N.
    Chuma, Stacey
    Kunsman, Janet
    Donovan, Amanda
    Bagshaw, Meghan
    Warren, Diane
    Anderson, Kenneth C.
    Richardson, Paul G.
    Weller, Edie
    Murphy, Timothy J.
    Matous, Jeffrey
    BLOOD, 2011, 118 (21) : 1164 - 1164
  • [28] Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
    Touzeau, Cyrille
    Chanan-Khan, Asher Alban Akmal
    Roberts, Andrew Warwick
    Agarwal, Amit
    Facon, Thierry
    Lebovic, Daniel
    Moreau, Philippe
    Darden, David E.
    Morris, Lura J.
    Ross, Jeremy A.
    Salem, Ahmed H.
    Munasinghe, Wijith
    Zhu, Ming
    Leverson, Joel
    Enschede, Sari H.
    Humerickhouse, Rod
    Harrison, Simon J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Hajek, Roman
    Pour, Ludek
    Ozcan, Muhit
    Sanchez, Jesus Martin
    Sanz, Ramon Garcia
    Anagnostopoulos, Achilles
    Oriol, Albert
    Cascavilla, Nicola
    Terjung, Andreas
    Lee, Yihua
    Briso, Eva M.
    Dobkowska, Edyta
    Hauns, Bernhard
    Spicka, Ivan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442
  • [30] CLINICAL RESPONSE BY BASELINE CHARACTERISTICS IN PATIENTS WITH RELAPSED AND BORTEZOMIB-REFRACTORY MULTIPLE MYELOMA TREATED WITH PANOBINOSTAT, BORTEZOMIB, AND DEXAMETHASONE (PANORAMA 2)
    Richardson, P.
    Schlossman, R.
    Alsina, M.
    Coutre, S.
    Gasparetto, C.
    Mukhopadhyay, S.
    Ondovik, M.
    Khan, M.
    Paley, C.
    Lonial, S.
    HAEMATOLOGICA, 2013, 98 : 324 - 324
12345